- Home
- JSPRW
JSPRW
Japer Therapeutics Inc.
as 02-21-2025 4:00pm EST
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | REDWOOD CITY |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 7.8K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.67 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.15 - $0.16 | Next Earning Date: | 03-05-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Japer Therapeutics Inc. News
JSPRW Breaking Stock News: Dive into JSPRW Ticker-Specific Updates for Smart Investing
GlobeNewswire
12 days ago
Jasper Therapeutics Announces Briquilimab Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
GlobeNewswire
18 days ago
Jasper Therapeutics to Present at the Oppenheimer Healthcare Life Sciences Conference
GlobeNewswire
a month ago
Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria
GlobeNewswire
2 months ago
Jasper Therapeutics to Host Webinar to Present Preliminary Data from the BEACON Study of Briquilimab in Chronic Spontaneous Urticaria on January 8, 2025
GlobeNewswire
3 months ago
Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a ETESIAN Clinical Study of Briquilimab in Asthma
Simply Wall St.
3 months ago
We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate
GlobeNewswire
3 months ago
Jasper Therapeutics to Participate at Upcoming Investor Conferences
GuruFocus.com
3 months ago
Analysts Bullish on Jasper Therapeutics as Briquilimab Trials Show Promise
Compare JSPRW vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "JSPRW Japer Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.